Objective-Transintestinal cholesterol excretion (TICE) is an alternate pathway to hepatobiliary secretion. Our study aimed at identifying molecular mechanisms of TICE. Approach and Results-We studied TICE ex vivo in mouse and human intestinal explants, and in vivo after bile diversion and intestinal cannulation in mice. We provide the first evidence that both low-density lipoprotein (LDL) and high-density lipoprotein deliver cholesterol for TICE in human and mouse jejunal explants at the basolateral side. Proprotein convertase subtilisin kexin type 9 (PCSK9) −/− mice and intestinal explants show increased LDL-TICE, and acute injection of PCSK9 decreases TICE in vivo, suggesting that PCSK9 is a repressor of TICE. The acute repression was dependent on the LDL receptor (LDLR). Further, TICE was increased when mice were treated with Lovastatin. These data point to an important role for LDLR in TICE. However, LDLR −/− mice showed increased intestinal LDL uptake, contrary to what is observed in the liver, and tended to have higher TICE. We interpret these data to suggest that there might be at least 2 mechanisms contributing to TICE; 1 involving LDL receptors and other unidentified mechanisms. Acute modulation of LDLR affects TICE, but chronic deficiency is compensated for most likely by the upregulation of the unknown mechanisms. Using mice deficient for apical multidrug active transporter ATP-binding cassette transporter B1 a and b, and its inhibitor, we show that these apical transporters contribute significantly to TICE. Conclusions-TICE is operative in human jejunal explants. It is a metabolically active process that can be acutely regulated, inversely related to cholesterolemia, and pharmacologically activated by statins. (Arterioscler Thromb Vasc
xcess cholesterol must be eliminated from the body to avoid its accumulation in tissues and to prevent or diminish atherosclerosis. The hepatobiliary pathway has been considered as the major cholesterol elimination route. Nevertheless, the existence of a nonbiliary route contributing to fecal sterol loss was revealed decades ago in dogs, 1 rats, 2 and later in humans 3 with impaired biliary secretion. More recently, a normal fecal cholesterol excretion rate was observed in mice deficient for cholesterol biliary excretion attributable to the absence of the canalicular phospholipid transport multidrug resistance 2 or to the overexpression of hepatic Niemann-Pick C1-Like 1. 4, 5 Normal or lower biliary cholesterol excretion and increased fecal sterol loss were also observed in mice with no or dramatically less liver cholesterol esterification by the enzyme acylcoenzyme A:cholesterol acyltransferase 2. 6 Transintestinal cholesterol excretion (TICE) is now recognized as a significant alternative route to the hepatobiliary pathway. 7 It has been estimated that TICE represents constitutively 33% of total fecal sterol loss in mice. 8 More recently, Temel et al 5 showed that TICE is essential to macrophage reverse cholesterol transport in mice suggesting a potential antiatherogenic role for TICE. Intestinal cholesterol excretion is inducible nutritionally by a high-fat diet 9 or pharmacologically by ligands of liver X receptor 8 or peroxisome proliferator activated receptor-δ, 10 but the molecular mechanisms remain unknown. plasma cholesterol through the endocytosis of apolipoprotein (apo) B-containing LDL 11 particles or apoE-coated lipoproteins, such as large high-density lipoprotein (HDL) or chylomicrons and very low-density lipoprotein remnants. Another important receptor, scavenger receptor B1, binds preferentially to apoAI and mediates the selective uptake of esterified cholesterol from HDL. 12 Scavenger receptor B1-deficient mice present with increased TICE. 9 Beside the liver, LDLR is expressed in many tissues, including the intestine where it is localized on the basolateral side of enterocytes. 13 Experiments in rats infused with LDL showed that intestinal LDLR mediates 60% of the LDL uptake. 14 In the liver and in the intestine, the quantity of cell surface LDLR results from a balance between its synthesis and degradation. Cellular cholesterol depletion and cholesterol synthesis inhibitors like statins increase the LDLR transcription via the activation of the sterol response element binding protein 2 pathway. 11 Plasma proprotein convertase subtilisin kexin type 9 (PCSK9) induces the LDLR degradation because it binds to the extracellular domain of the LDLR and prevents its recycling to the cell surface. 15 Thus, mice deficient in PCSK9 have more LDLR protein in the liver 16 and in the intestine. 17 The functional importance of intestinal LDLR and its circulating regulator PCSK9 in TICE remains to be explored.
Efflux of free cholesterol from the apical side of the enterocytes mainly takes place via ATP-binding cassette transporter G5/ATP-binding cassette transporter G8 (ABCG5/G8). 18 TICE is reduced by only 40% in ABCG5-deficient mice, 8 suggesting that TICE-derived cholesterol exit enterocytes via other cholesterol transporters. P-Glycoprotein (P-gp; multidrug resistance-1 [MDR1]) or ATP-binding cassette transporter B1 (ABCB1) belonging to the ATP-binding cassette family is an integral membrane protein expressed in most epithelial cells, notably in the liver and at the apical side of enterocytes. It exports a large variety of structurally unrelated compounds out of cells and out of organisms protecting tissues from xenobiotic toxicity.
19 ABCB1 is also involved in the movement of endogenous molecules, such as cholesterol, phospholipids, and sphingolipids, 20 and a variety of steroids. 21 Although its role in cholesterol efflux per se remains controversial, 22 it has been shown that ABCB1 contributes to cholesterol distribution from the cytosolic leaflet to the exoplasmic leaflet of the plasma membrane by acting as a floppase. 23 Although the existence of TICE per se is not debated, the nature of the phenomenon remains unclear. The main missing elements are (1) a molecular mechanism for cholesterol entry on the basal side of enterocytes; (2) a direct evidence of TICE in intestinal explants, in particular, in human tissues; (3) data showing an increase of TICE in the context of lower cholesterolemia; (4) the contribution of apical transporters; and (5) acute modulation of TICE. The present study was developed to fill these gaps.
Material and Methods
Material and Methods are available in the online-only Supplement.
Results

TICE Is an Active Metabolic Process
To develop an ex vivo assay for TICE, we mounted mouse duodenal explants in Ussing chambers and added LDL (0.7 mg/mL) radiolabeled with 3 H-free cholesterol ( 3 H-LDL) to the basolateral side of duodenal mouse explants and incubated at 37°C or 4°C. After 30 minutes and at 37°C, 0.07% of the initial dose of 3 H-cholesterol present in the basal chamber was collected into the apical chamber. We determined the passage of cholesterol to the apical chamber >90 minutes (3×30 minutes), and the radioactive content remained in the explants at the end of the experiment. We verified that TICE and 3 H-cholesterol intestinal content values were stable over the first, the second, and the last period of 30-minute measurement (data not shown).
3 H-LDL TICE ( Figure 1A ) and uptake ( Figure 1B) were repressed by cold temperatures. Next, we measured TICE from 3 H-LDL in explants over 3 consecutive periods of 30 minutes in the presence or absence of oxygen in the media ( Figure 1C) ; TICE was observed when media were oxygenated. In group C, oxygenation-induced TICE is stronger when the oxygenated period is consecutive to a 30-minute phase without oxygen. This could be attributable to cells being loaded with cholesterol during the nonoxygenated period. This might mean that oxygen is important to cholesterol efflux. As a control, we verified that bubbling of N 2 instead of oxygen had no effect on TICE (data not shown). TICE was not secondary to cytotoxicity as there was no significant increase in lactate dehydrogenase under different conditions ( Figure 1D ). Next we measured the impact on TICE of apical cholesterol acceptors present in Figure 1A -1D ( Figure 1E ). Removing cholesterol acceptors from the apical chamber significantly reduced TICE. No cytotoxicity associated with the presence of cholesterol acceptor was detected and, therefore, we systematically used cholesterol acceptors, unless stated. Therefore, transport of 3 H-LDL cholesterol is attributable to an active metabolic pathway when explants were provided with oxygenated media at 37°C. To our knowledge, this is the first report of a method to measure TICE ex vivo.
Both HDL and LDL Provide Cholesterol for TICE
To determine whether HDL and LDL contribute to TICE, we added H-cholesterol-labeled low-density lipoprotein (LDL; 3 H-LDL) was added to the Krebs/glucose buffer at the basolateral side. A, TICE was determined by measuring the appearance of radioactivity at the apical side and uptake of was measured by quantifying radioactivity in the explants incubated at 37°C or 4°C (n=8-16 explants from 4 to 8 mice per group) (B). Results represent the average of TICE measured over 3 periods of 30 minutes. C, TICE was measured at 37°C in 3 groups of C57Bl6J explants for 3 consecutive phases of 30 minutes (1, 2, 3). In group A, the buffers were not oxygenated. In group B, buffers were constantly oxygenated. In group C, buffers were oxygenated only during the second period of 30 minutes (n=8-10 explants from 8 to 10 mice per group). D, The effect of oxygenation on lactate dehydrogenase (LDH) release was measured in the apical chamber at 37°C in 2 groups of C57Bl6J explants for 2 consecutive phases of 30 minutes (4 explants per condition from 4 mice). In group D, the buffers were not oxygenated during the first 30-minute period (1) and were oxygenated for the second 30-minute period (2) . In group E, explants were oxygenated for the first period but not during the second one. E, C57Bl6J mouse proximal intestinal explants were mounted on Ussing chambers.
3 H-cholesterollabeled LDL ( 3 H-LDL) was added to the Krebs/glucose buffer at the basolateral side. TICE was determined by measuring the appearance of radioactivity at the apical side over 30 minutes during 2 consecutives conditions: with a buffer containing cholesterol acceptors (taurocholate/phosphatidylcholine, 10/2 mmol/L; Black bar) or without acceptors. Cell cytotoxicity was assessed in the apical chamber during the 2 periods of 30 minutes by measuring LDH release in the apical chamber. All values represent mean±SEM. **P<0.05, ***P<0,001. For positive cytotoxic effects, explants were exposed to a cell lysis solution containing Triton-X-100. NS indicates nonsignificant.
TICE Is Operative in Human Intestine
There has been no evidence of TICE in humans yet. Using an Ussing Chamber, we measured TICE with 3 H-LDL and 3 H-HDL in jejunal explants from 3 patients who underwent bariatric surgery ( Figure 2C ). Explants were collected 50 cm below duodenojejunal flexure for the all patients. We also compared TICE in the absence or in the presence of cholesterol acceptors in the apical chamber. TICE was operative in human explants. The presence of cholesterol acceptors (taurocholate/phosphatidylcholine, 10/2 mmol/L) increased TICE by roughly 100% for 3 H-LDL and 300% to 400% for 3 H-HDL. Thus, human intestine might play a role in TICE.
PCSK9 Deficiency Increases TICE
To determine whether the LDLR can contribute to TICE, we measured TICE derived from LDL in PCSK9 −/− mice that present with higher amounts of LDLR in their gut, as we previously showed. 17 LDL-TICE was increased by 103% (P<0.05) in duodenal explants from PCSK9 −/− mice, compared with explants from PCSK9 +/+ ( Figure 3A) . Next, we verified these results in vivo. PCSK9 −/− mice have ≈50% less plasma cholesterol than littermates because of an increased clearance of HDL and LDL, respectively, via the apoE and apoB. 16 We measured TICE with 
Acute Degradation of LDLR by PCSK9 Decreases TICE
Next we verified whether acute depletion of LDLR decreases TICE. It has been shown that injection of recombinant 
Figure 2. Both low-density lipoprotein (LDL) and high-density lipoprotein (HDL) contribute to transintestinal cholesterol excretion (TICE).
A, C57Bl6J mouse proximal intestinal explants were mounted on Ussing chambers. H-HDL (specific activities of 119 CPM/ nmol and 116 CPM/nmol, respectively) was added to Krebs/glucose buffer in the basolateral chamber (n=16-19 explants from 10 mice per group). After 30 minutes, TICE was determined by measuring the appearance of radioactivity in the apical chamber filled with Krebs buffer enriched with cholesterol acceptors (taurocholate/phosphatidylcholine; TC/PC: 10/2 mmol/L). B, 3 H-LDL or 3 H-HDL (specific activities of 1494 CPM/nmol and 1088 CPM/nmol, respectively) was injected in the penile vein of C57Bl6J mice (6-8 mice per group) and transintestinal 3 H-cholesterol excretion was measured >2 hours by quantifying radioactivity in perfusates collected from cannulated intestinal segments. C, Jejunal explants from 3 patients were mounted on Ussing chambers. Equal amounts of 3 H-cholesterol contained in PCSK9 in the circulation rapidly degrades the hepatic and extrahepatic LDLR. 25, 26 We first measured TICE in PCSK9 −/− mice, 1 hour after they were intravenously injected with 100 μg recombinant PCSK9. 25 Western blot analysis showed that the LDLR content of the duodenum was reduced within 1 hour ( Figure 3E ). As expected, increases in cholesterol after the injection of 3 H-LDL were more pronounced in mice infused with PCSK9 ( Figure 3C ; Figure III in the onlineonly Data Supplement). TICE was decreased by ≈35% in these mice ( Figure 3D ). As a control, PCSK9 was injected in LDLR −/− mice ( Figure 3C and 3D) . LDLR −/− mice presented with 40% higher TICE in absolute value than PCSK9 −/− mice (data not shown). It is unclear whether this is because of very active TICE in LDLR −/− mice or to the difference in genetic background between strains. Indeed, Van der Velde et al 24 showed that mice of different genetic backgrounds have different levels of TICE. Nevertheless as expected, no effect of injected PCSK9 was observed on cholesterolemia nor on TICE in LDLR −/− mice. These studies show that circulating PCSK9 acutely decreases TICE in an LDLR-dependent fashion.
Lovastatin Stimulates TICE
Next we hypothesized that cholesterol synthesis inhibitors, such as statins, that upregulate LDL receptors could stimulate TICE. To test this hypothesis, C57Bl6J mice were given a diet containing or not 0.02% Lovastatin for 10 days. This treatment decreased cholesterolemia by ≈18% (P<0.05; Figure  4A 
TICE Is Increased in the Absence of LDLR
The above studies involving modulation of LDLR by PCSK9 and Lovastatin indicated that LDLR might play an important role in TICE. Therefore, we hypothesized that TICE might be significantly reduced in LDLR −/− mice. Chronic LDLR deficiency results in delayed LDL plasma clearance 27 because of less binding of LDL particles in the liver. 28 To evaluate whether TICE is affected by the absence of LDLR, we compared TICE in C57Bl6J and LDLR −/− mice using 3 H-LDL. In contrary to what was expected, we observed that TICE is slightly higher in LDLR −/− mice than in C57Bl6 in vivo (P=0.055; Figure 5A ; Figure V in the online-only Data Supplement). TICE also tended to be increased in LDLR −/− explants (P=0.28; Figure 5B ). In both experiments, the differences were not statistically significant but the trends were reproducible over time. To explain no reduction in TICE in LDLR −/− mice, we studied the uptake of 125 I-LDL by the various intestinal segments in C57Bl6J and LDLR −/− mice after intravenous injections. Clearance from plasma was determined at various time points and radioactive content of liver and intestinal segments at 2 hours after injection; a duration equivalent to that we used for in vivo TICE ( Figure  5D ). We observed a delay in 125 I-LDL clearance in LDLR −/− mice and a reduction of 125 I-LDL hepatic uptake (−24%; P<0.05) consistent with other studies. 27, 28 There was no significant difference in radioactive uptake by the medial and distal intestinal segments, but a significant increase in radioactivity was seen in the proximal segment. Thus, contrary to what occurs in the liver, chronic LDLR deficiency results in increased LDL uptake in the proximal intestine. This might contribute to increased TICE.
ABCB1 Contributes to TICE
Next we focused on molecules that could efflux cholesterol from the apical side of enterocytes. ABCG5 contributes to TICE, 8 probably because of its important role in cholesterol efflux. However, ABCG5
−/− mice still have an appreciable level of TICE, suggesting that other apical transporters play a role in TICE. Among the candidates, multidrug transporter ABCB1, which is located at the apical pole of enterocyte, can act as a cholesterol floppase. 23 We recently showed that older mice deficient for both isoforms of the apical cholesterol floppase ) spontaneously develop hepatic steatosis, obesity, diabetes mellitus, and increased HDL-C. 29 We performed our studies in 15-week-old male mice that presented with similar cholesterol levels ( Figure VIA in the online-only Data Supplement), before metabolic disturbances arise. We observed that ABCB1a/b −/− mice present with 26% less fecal cholesterol excretion (P<0.05; Figure 6A ). Next, we injected intravenously Figure 6B ). We further verified involvement of ABCB1a/b in TICE using pharmacological inhibitors ( Figure 6C ). We added ABCB1 reference inhibitor PSC-833 30 to the apical chamber. Thirty minutes after the addition of 3 H-cholesterol/endolipid to the basal chamber, the medium was collected in the apical chamber for determination of 3 H-cholesterol level (initial TICE). The apical chamber was rinsed and PSC-833 was added with new medium for 30 minutes. TICE observed with no inhibitor was arbitrarily set at 1. PSC-833 inhibited TICE by 50% to 64% (P<0.05) in control mice but had no effect in ABCB1a/b −/− mice. These studies provide evidence that ABCB1a/b contribute to TICE.
Discussion
These results fill a gap in our understanding of plasma cholesterol excretion by the small intestine. We demonstrate that both LDL and HDL provide cholesterol for TICE in vivo and ex vivo in mice. Further, we provide the first direct evidence that human intestinal explants can excrete plasma-derived LDL or HDL cholesterol. On the basis of these studies, we propose a model (Figure 7 ) in which both LDL and HDL can contribute to TICE, a metabolically active pathway present in mice and humans. LDL-TICE can be modulated positively by statins and negatively by PCSK9. In addition, the multidrug transporter ABCB1 contributes to the luminal efflux of cholesterol.
TICE has generally been studied by injecting 3 H-cholesterol as part of intralipid emulsions. Our studies demonstrate that cholesterol present as part of plasma lipoproteins is amenable to TICE. How do these lipoproteins contribute to TICE? Studies in mice deficient for hepatic acyl-coenzyme A:cholesterol acyltransferase 2, 6 where hepatic cholesterol cannot be esterified and stored, and recent findings in mice with impaired hepatobiliary cholesterol excretion 5 suggest that cholesterol is first delivered to the liver before being rerouted to the intestine for excretion. Our findings do not exclude this possibility. However, our ex vivo experiments reveal that LDL and HDL can directly provide cholesterol to the intestine for TICE. While this article was in preparation, Vrins et al 31 published a study stating that TICE is not mediated by HDL. Overall, the main point of this article is that TICE derived from radiolabeled HDL is much lower than TICE measured after injection of 3 H-cholesterol diluted in a mixture of lipids. In particular, HDL-derived TICE seems to be roughly 10× lower than biliary cholesterol excretion. For comparison, the authors ) . B, TICE was measured in these animals after injecting 3.5 µCi 3 H-cholesterol diluted in 20% endolipid. C, TICE was measured in explants from mice of the same age and sex (n=6 explants per condition from 6 mice).
3 H-cholesterol diluted in endolipid was added to the basal chamber to determine initial TICE for 30 minutes. Apical media was switched to new media with the same composition or containing ABCB1a/b inhibitor PSC-833, and TICE was measured after 30 minutes. The results represent the mean of TICE for each genotype, relative to control (no PSC-833) arbitrarily set at 1. Values represent mean±SEM. *P<0.05.
determined that lipid emulsions contribute twice as much to TICE compared with biliary excretion. Specific activity in the bile was also 10× lower when using HDL compared with lipid emulsions, but the doses of 3 H-CO injected were 5× lower. Further, HDL-TICE was actually measurable and unfortunately no other lipoproteins, such as LDL, were used for comparison. Thus, we believe that under the experimental conditions used by these investigators, HDL is much less efficient than intralipid.
In this study, we used LDL and HDL. The importance of triglyceride-rich lipoproteins or remnants in TICE was not explored here. A study suggested that triglyceride-rich emulsion particles are not cleared directly by the small intestine but are rapidly taken in by the liver. 8 Cholesterol is then secreted into the plasma mainly on HDL. 31 More experiments are required to address the role of larger triglyceride-rich lipoproteins in TICE.
Using a genetic model (PCSK9 −/− mice) and pharmacological treatment (Lovastatin), we showed for the first time that TICE and cholesterolemia can be inversely related. Lovastatin-treated and PCSK9 −/− -injected mice have low plasma cholesterol and yet show increased TICE. Thus, TICE does not seem to be a concentration-dependent passive process. This observation was further supported by ex vivo studies showing that TICE occurs at physiological temperatures and in the presence of oxygen. Therefore, TICE seems to be an active process.
We observed that Lovastatin increased LDL-derived TICE in C57Bl6J mice. The effect of Lovastatin was also investigated in parallel in LDLR −/− mice and Lovastatin reproducibly failed to increase TICE in the absence of LDLR (data not shown). However, we cannot exclude that TICE reached a plateau in LDLR −/− mice under Lovastatin. Thus, more work is needed to fully understand the relevance of the modulation of LDLR to TICE.
As discussed above, our data show that modulation of LDLR expression by PCSK9 and statins affects TICE. However, we were surprised to see that TICE was not decreased in LDR −/− mice. To explain these apparent contradictory findings, we propose that uptake of LDL by the intestine that contributes to TICE might involve several mechanisms. Comodulation of LDLR and TICE by PCSK9 and statins suggests that LDLR plays a role in TICE in WT mice. However, in LDLR −/− mice TICE is not reduced suggesting that other unknown mechanism(s) might have been upregulated to compensate for genetic deficiency of LDLR. This is consistent with the observations showing increased gastrointestinal sterol cholesterol excretion in patients with homozygous familial hypercholesterolemia and bile diversion. 3 The nature of this unknown mechanism(s) remains to be elucidated. There are several possible candidates that can be tested in the future, such as LDLR-related protein 1 that is expressed in the intestine, 32 the very low-density lipoprotein receptor which is a also degraded by PCSK9, 33 Sortilin 1, 34 and proteoglycans. 35 Of note, although apoE receptor lowdensity lipoprotein receptor-related protein 1 does not clear LDL under normal conditions, LDLR −/− mice do accumulate apoE in their plasma and present with apoE on LDL. 36, 37 Thus, it is possible that excess plasma apoE bound LDL after their injection in LDLR −/− mice. Besides LDL, we also show that HDL-derived cholesterol is also amenable to TICE. It is unclear yet which receptor on Model transintestinal cholesterol excretion (TICE) is an active metabolic pathway that involves both low-density lipoprotein (LDL) and high-density lipoprotein (HDL). On the basal side of proximal intestine enterocytes, LDL-mediated TICE is induced by statins. TICE is repressed by proprotein convertase subtilisin kexin type 9 (PCSK9) in an LDLR fashion, but LDL-mediated TICE is present in LDLR-deficient mice suggesting that undefined alternative pathway exists. The HDL receptor(s) responsible of the HDL-mediated TICE remain(s) to be determined. On the apical side, efflux of cholesterol is mediated at least by ATP-binding cassette transporter G5/ATPbinding cassette transporter G8 (ABCG5/G8) 8 and ABCB1a/b.
the basolateral side mediates HDL-TICE. Selective uptake of cholesterol esters from HDL is made possible by scavenger receptor B1. TICE has been found to be increased or unchanged in SRB-1 −/− mice. 9,31 Another possible entry gate for HDL cholesterol in TICE could be P2Y13/ectoF1-ATP synthase pathway, 38 although it is unclear whether this pathway is functional in the small intestine. Obviously, more work is needed to answer these questions.
Our data show that ABCB1 contributes to TICE. It is unclear why the effect seen in vivo in the absence of transporter was not more pronounced that that seen ex vivo with the inhibitor. Several human studies describe a link between cholesterol levels and ABCB1 gene polymorphisms. [39] [40] [41] Owing to its apical location in enterocytes, it is tempting to speculate that ABCB1 could work additively or in synergy with ABCG5/G8 transporter to manage the luminal efflux of cholesterol. It would be very interesting to characterize the effect of ABCB1 deletion/ inhibition in ABCG5/G8 knockout mice. Altogether results presented here provide evidence that TICE is an active process in human and in rodent intestine. Further, we identified molecules that could participate in this process.
